Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wipro Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Wipro Limited trades at $1.88 (market cap $18.38B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× Wipro Limited's market cap, and Wipro Limited pays a 10.25% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WIT | |
|---|---|---|
Market Cap | $39.89B | $18.38B |
Sector | Health | Technology |
52-Week High | $491.22 | $3.06 |
52-Week Low | $278.09 | $1.82 |
Enterprise Value | $38.15B | $14.77B |
Dividend Yield | — | 10.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
WIT trades at $1.87, up 1.08% today, but faces bearish technical signals with recent earnings misses in Q3 2025, Q4 2025, and Q1 2026. Fundamentals show solid profitability with a 14.25% net margin and 15.4% ROE, while valuation metrics like a P/E of 14.05 appear reasonable. Recent news highlights AI partnerships with ServiceNow and Anthropic, though weak Q2 2026 guidance has pressured sentiment.
The outlook is cautious with mixed analyst ratings (19% buy, 48% hold, 33% sell) and near-term revenue headwinds. Investment opportunities lie in AI-driven growth initiatives, but risks include execution challenges and competitive pressures in the IT services sector. Cash flow remains strong at $25.02B net for 2025, supporting financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
